Tango Therapeutics (TNGX) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Company overview and strategic focus

• Transitioned from a discovery organization to advancing a lead PRMT5 inhibitor, vopimetostat, now in pre-commercial and approval phases.

• Achieved a 92% overall response rate in a 12-patient pancreatic cancer cohort with vopimetostat and RAS inhibitor combinations.

• Hired a Chief Commercialization Officer to prepare for product launch and commercialization.

• Focused on evolving clinical data and preparing for regulatory submissions.

Clinical data and differentiation

• Vopimetostat targets MTAP-deleted cancers, representing a significant patient population across multiple tumor types.

• Demonstrated strong tolerability and combinability, with a favorable safety profile compared to other PRMT5 inhibitors.

• Combination with daraxonrasib reduced RAS inhibitor-related toxicities, potentially improving safety.

• Ongoing studies continue to enroll patients, with upcoming data updates planned for ESMO.

Regulatory and development strategy

• Main priority is developing the vopimetostat combination in frontline pancreatic cancer, with plans to discuss accelerated approval in second-line settings.

• Collaborating closely with Revolution Medicines and AstraZeneca to advance combination studies.

• Regulatory strategy includes engagement with FDA, EMA, and Japanese authorities, with more details expected by year-end.

• Significant timeline advantage over competitors, leveraging early and robust data for regulatory discussions.